

APC/Fire™ 750 anti-human CD94

Catalog # / 2127585 / 25 tests
Size: 2127590 / 100 tests

Clone: DX22

Isotype: Mouse IgG1, κ


Immunogen: NK cell line

Reactivity: Human, Non-human primate, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with APC/Fire™ 750 under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD94 (clone DX22) APC/Fire™ 750 (filled histogram) or Mouse IgG1, κ APC/Fire™ 750 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining volume or 5 μ l per 100 μ l of whole blood.

* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

Application Notes: Additional reported applications (for the relevant formats) include: immunoprecipitation⁴, inhibition of NK cell-mediated lysis⁵, and immunohistochemical staining of acetone-fixed frozen tissue sections.

Application References:

1. Mizuki M, et al. 2000. *Sarcoidosis Vasc. Diffuse Lung Dis.* 17:54.
2. Phillip J, et al. 1996. *Immunity* 5:163.
3. Lazetic S, et al. 1996. *J. Immunol.* 157:4741.
4. Lanier LL, et al. 1998. *Immunity* 8:693.
5. Wooden SL, et al. 2005. *J. Immunol.* 175:1383.

Description: CD94 is a 43 kD type II transmembrane glycoprotein also known as KP43. CD94 belongs to the C-type lectin superfamily and is present as a covalently linked heterodimer with NKG2 on the cell surface. CD94 is expressed by NK cells, a subset of $\gamma\delta$ T cells, and NKT cells. The CD94/NKG2A complex serves as an inhibitory receptor specific for HLA-class I molecules.

Antigen References:

1. Lopez-Botet M, et al. 1997. *Immunol. Rev.* 155:165.
2. Moretta A, et al. 1997. *Immunol. Rev.* 155:105.